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ABSTRACT
Objective: To compare the effect of two strategies
(enhanced hand hygiene vs meticillin-resistant
Staphylococcus aureus (MRSA) screening and
decolonisation) alone and in combination on MRSA
rates in surgical wards.
Design: Prospective, controlled, interventional cohort
study, with 6-month baseline, 12-month intervention
and 6-month washout phases.
Setting: 33 surgical wards of 10 hospitals in nine
countries in Europe and Israel.
Participants: All patients admitted to the enrolled
wards for more than 24 h.
Interventions: The two strategies compared were
(1) enhanced hand hygiene promotion and (2)
universal MRSA screening with contact precautions
and decolonisation (intranasal mupirocin and
chlorhexidine bathing) of MRSA carriers. Four
hospitals were assigned to each intervention and two
hospitals combined both strategies, using targeted
MRSA screening.
Outcome measures: Monthly rates of MRSA clinical
cultures per 100 susceptible patients (primary
outcome) and MRSA infections per 100 admissions
(secondary outcome). Planned subgroup analysis for
clean surgery wards was performed.
Results: After adjusting for clustering and potential
confounders, neither strategy when used alone was
associated with significant changes in MRSA rates.
Combining both strategies was associated with a
reduction in the rate of MRSA clinical cultures of 12%
per month (adjusted incidence rate ratios (aIRR) 0.88,
95% CI 0.79 to 0.98). In clean surgery wards, strategy
2 (MRSA screening, contact precautions and
decolonisation) was associated with decreasing rates of
MRSA clinical cultures (15% monthly decrease, aIRR
0.85, 95% CI 0.74 to 0.97) and MRSA infections (17%
monthly decrease, aIRR 0.83, 95% CI 0.69 to 0.99).
Conclusions: In surgical wards with relatively low
MRSA prevalence, a combination of enhanced standard
and MRSA-specific infection control approaches was
required to reduce MRSA rates. Implementation of
single interventions was not effective, except in clean
surgery wards where MRSA screening coupled with
contact precautions and decolonisation was associated
with significant reductions in MRSA clinical culture and
infection rates.
Trial registration: clinicaltrials.gov identifier:
NCT00685867
INTRODUCTION
Healthcare associated infections affect hun-
dreds of millions of patients worldwide every
year and represent an important cause of
patient mortality and a major ﬁnancial
burden to health systems.1 Meticillin-resistant
Staphylococcus aureus (MRSA), now endemic
in many healthcare facilities, is a leading
cause of healthcare associated infections2
and patients in surgical units are at increased
risk due to factors such as invasive proce-
dures, antibiotic exposure and prolonged
healthcare contact. A number of countries
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Unlike many previous studies, this was a large,
controlled, prospective, multicentre, intervention
study. The enrolled wards, from 10 hospitals in
Europe and Israel, varied in terms of infection
control infrastructure and meticillin-resistant
Staphylococcus aureus prevalence, thus the
results are likely to be generalisable to other
settings.
▪ Due to the nature of the quality improvement
initiatives, investigators were not blinded to the
allocated intervention. Interventions were not
randomly allocated.
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mandate implementation of control measures, including
MRSA screening.3 4 Not all mandated interventions,
however, are supported by robust evidence.
Studies evaluating MRSA control strategies show con-
ﬂicting results, particularly with regard to the use of
active surveillance cultures.5–7 It is argued that broader
infection control approaches, such as improving hand
hygiene (HH) practices, may be as successful as
MRSA-speciﬁc strategies.8 9 There are limitations,
however, to current evidence with few prospective, con-
trolled studies10 11 and many studies have assessed mul-
tiple interventions simultaneously.12 Quantifying the
relative beneﬁts of individual approaches is important,
particularly as some strategies have signiﬁcant cost impli-
cations, and will allow efﬁcient use of limited resources.
Owing to the ongoing debate concerning optimal
approaches to MRSA control,13 14 we performed a pro-
spective, interventional, quality improvement study to
compare the effect of an enhanced HH promotion strat-
egy to an MRSA screening, isolation and decolonisation
strategy when used alone and in combination on the
incidence rates of MRSA clinical cultures and infections
in surgical patients admitted to healthcare facilities
across Europe and Israel. We also aimed to speciﬁcally
assess these interventions in clean surgery wards where
their beneﬁts may be expected to be more pronounced.
METHODS
Study design and population
This prospective, controlled, multicentre, interventional
cohort study with a three phase interrupted time series
design was conducted between March 2008 and July
2010. Thirty-three surgical wards of 10 hospitals in nine
countries (Serbia, France, Spain (two hospitals), Italy,
Greece, Scotland, Israel, Germany and Switzerland) were
enrolled. Wards included orthopaedic (8), vascular (6),
cardiothoracic/cardiovascular (5), general (4), abdom-
inal (4), urology (3), neurosurgery (2) and plastic
surgery (1) subspecialties. Characteristics of the enrolled
wards varied (table 1).
The study consisted of baseline (6–7 months), inter-
vention (12 months) and washout (6 months) phases.
Initial baseline phase data collection started in one
centre in March 2008 prior to the implementation of
any interventions. All other centres started baseline
phase data collection after May 2008. The intervention
phase did not start for any study site until October 2008.
During baseline and washout phases, wards employed
their usual infection control practices. During the inter-
vention phase, two strategies were investigated, with hos-
pitals implementing one or both interventions in
parallel (ﬁgure 1).
Interventions
The ﬁrst intervention, the enhanced HH strategy, used
the WHO multimodal HH promotion method consisting
of (1) using alcohol-based handrub at the point of care,
(2) training and education of healthcare workers, (3)
observation and feedback of HH practices, (4) remin-
ders in the workplace (eg, posters) and (5) improving
the safety climate in the institution with management
support for the initiative.15 Adherence to standard pre-
cautions (eg, gloves for body ﬂuid contact) was encour-
aged. There was no attempt to change local practices
regarding isolation of patients with MRSA as part of this
intervention.
The second intervention, the screening and decolon-
isation strategy, used a universal MRSA screening
approach. It consisted of screening patients admitted for
more than 24 h for MRSA, on admission (within 48 h)
then weekly. Patients were excluded from screening if
they were undergoing ambulatory surgery or had already
been screened within 5 days prior to admission to the
surgical ward. The nares, perineum and wounds (if
present) were swabbed. Chromogenic agar screening
was used with the addition of PCR testing during the
latter part of the intervention phase for patients who
had risk factors for MRSA (eg, hospitalisation in the last
year) whose chromogenic agar results were unlikely to
be available before surgery. MRSA carriers were placed
on contact precautions (gown and gloves during patient
contact), administered decolonisation therapy with twice
daily intranasal mupirocin and daily chlorhexidine
washes for 5 days and perioperative prophylaxis was
modiﬁed to reﬂect MRSA carriage. Chlorhexidine
bathing was limited to the identiﬁed MRSA carriers and
not used as a unit-wide intervention. Pre-emptive isola-
tion was not used as part of this strategy.
The hospital was the unit for assignment of interven-
tions due to practical reasons and the nature of the strat-
egies. Four hospitals were assigned to each intervention
and two hospitals used a combination of both strategies
(the combined strategy) due to the introduction of
national or local mandatory targeted MRSA screening
policies during the study period which necessitated devi-
ation from the original trial protocol (ﬁgure 1). The
choice of allocation was inﬂuenced by the constraints on
the study centres, such as cost and personnel (n=3),
population size (n=1), capacity of the microbiology
laboratories (n=3), prior exposure to speciﬁc interven-
tions (n=1) and mandatory local or national interven-
tions (n=2). Thus, this pragmatic approach took into
account the institutions’ preferences, as participation in
an entirely cluster-randomised trial would have meant
that some of the hospitals could not have participated.
The targeted screening in the two hospitals in the
combined strategy arm was based on risk factors for
MRSA carriage (including patient characteristics or sur-
gical subspecialty). One hospital using the combined
strategy (hospital 4) introduced targeted screening of
patients who were previously known to be MRSA posi-
tive, contacts of patients with MRSA and patients trans-
ferred from the intensive care unit or other healthcare
facilities. The other hospital in the combined strategy
arm (hospital 7) not only used targeted screening of
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Table 1 Baseline phase characteristics of hospitals and wards enrolled in the study
Hospital
Hospital characteristics Study ward characteristics
Study arm
Total
beds (n)
Total
number
of single
rooms
(%)
Ratio of
infection
control
nurses to
beds
Surgical
subspecialties
Total
beds
(n)
Total
admissions
during
baseline
phase (n)
Mean
patient-to-nurse
ratio (SD)*
Per cent
hand hygiene
compliance
(95% CI)
Number of
patients
screened
on
admission
(%)
Number
identified
MRSA
positive
on
admission
(%)†
1 3611 45 (1.2) 1:240 Abdominal 588 8018 6.4 (1.2) 18.8 (15.1 to 22.9) 0 (0) 9 (0.1) Enhanced hand
hygiene
Cardiovascular
Orthopaedic
2 317 235 (74.1) 1:160 Cardiothoracic 72 1613 4.1 (1.8) 75.4 (70.3 to 80.0) 29 (1.8) 20 (1.2) Screening and
decolonisation
Orthopaedic
Vascular
3 850 135 (15.9) 1:425 Cardiovascular 75 1841 5.6 (0.7) 26.8 (24.4 to 29.4) 14 (0.8) 11 (0.6) Screening and
decolonisation
General
Orthopaedic
4 822 0 (0) 1:137 Abdominal 230 6574 3.7 (0.9) 39.3 (34.6 to 44.1) 182 (2.8) 21 (0.3) Combined
Orthopaedic
Urology
Vascular
5 545 89 (16.3) 1:272 General 121 1938 5.8 (1.5) 14.3 (11.3 to 17.6) 56 (2.9) 4 (0.2) Screening and
decolonisation
Neurosurgery
Orthopaedic
Vascular
6 547 4 (0.7) 1:274 General 93 1300 16.8 (2.5) 25.1 (20.7 to 30.1) 0 (0) 5 (0.4) Screening and
decolonisation
Orthopaedic
Vascular
7 902 62 (6.9) 1:180 Abdominal 84 1963 6.1 (1.5) 76.5 (71.3 to 81.1) 607 (30.9) 41 (2.1) Combined
General
Vascular
8 850 202 (23.8) 1:567 Orthopaedic 87 2434 5.5 (0.6) 50.2 (44.6 to 55.8) 0 (0) 3 (0.1) Enhanced hand
hygiene
Urology
Vascular
Continued
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Table 1 Continued
Hospital
Hospital characteristics Study ward characteristics
Study arm
Total
beds (n)
Total
number
of single
rooms
(%)
Ratio of
infection
control
nurses to
beds
Surgical
subspecialties
Total
beds
(n)
Total
admissions
during
baseline
phase (n)
Mean
patient-to-nurse
ratio (SD)*
Per cent
hand hygiene
compliance
(95% CI)
Number of
patients
screened
on
admission
(%)
Number
identified
MRSA
positive
on
admission
(%)†
9 1350 150 (11.1) 1:260 Cardiothoracic 164 1561 10.0 (2.2) 67.0 (61.4 to 72.3) 17 (1.1) 15 (1.0) Enhanced hand
hygiene
Neurosurgery
Plastic surgery
10 2044 402 (19.7) 1:204 Abdominal 302 6366 4.8 (0.4) 55.9 (51.2 to 60.5) 1666 (26.2) 140 (2.2) Enhanced hand
hygiene
Cardiovascular
Orthopaedic
Urology
Overall 11 838 1324 (11.2) 1816 33 608 6.6 (3.8) 39.5 (38.1 to 40.9) 2571 (7.6) 269 (0.8)
*Calculated by dividing the mean patient load by mean number of nurses working on the ward at a given time (averaged over day, evening and night shifts).
†By screening or clinical culture.
MRSA, meticillin-resistant Staphylococcus aureus.
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patients with the same risk factors as hospital 4, but also
screened nursing home residents, patients admitted to
the hospital in the last 3 months, patients transferred
from another ward within the same hospital and those
admitted to vascular or abdominal surgery subspecialties.
The assignment of hospitals to each study arm occurred
prior to the start of the data collection. A summary of
the nature of the interventions for each study arm is pre-
sented in table 2. The study protocol was registered with
a public registry of clinical studies (available at: http://
clinicaltrials.gov/ Identiﬁer: NCT00685867).
Outcome measures
The primary outcome measure was the monthly nosoco-
mial MRSA isolation rate, deﬁned as the number of
MRSA clinical isolates (those from specimens collected
other than for screening purposes, counting one isolate
per patient per month), per 100 susceptible patients
(not previously known to be MRSA colonised or
infected). Isolates from specimens collected more than
48 h after admission or within 30 days after discharge
from study wards were considered nosocomial.
Secondary outcomes were the monthly rate of nosoco-
mial MRSA infections per 100 admissions and adherence
to HH guidelines and contact precautions. Infections
were deﬁned using Centers for Disease Control and
Prevention (CDC) criteria.16 Adherence to HH guide-
lines was measured as the percentage of opportunities for
HH in which staff used alcohol-based handrub and/or
washed their hands according to the WHO method.15
Adherence to contact precautions was measured as the
percentage of randomly audited patients with MRSA for
whom precautions with gown and gloves during patient
contact had been implemented.
Microbiological methods
Standardised laboratory manuals were provided to
centres. Samples were processed in local laboratories
using standard culture-based identiﬁcation of MRSA
from clinical specimens. In hospitals assigned to the
screening and decolonisation arm, nasal and perineal
swabs were pooled in the laboratory then plated directly
onto a chromogenic medium (BBL CHROMagar MRSA
II, BD Diagnostics, Belgium) and also incubated over-
night in an enrichment medium to increase test sensitiv-
ity.17 Positive results could be reported within 24–48 h.18
PCR testing directly from pooled screening swabs was per-
formed with the BD GeneOhm MRSA (BD Diagnostics,
Belgium) or GeneXpert MRSA (Cepheid, Belgium) tests,
which have turnaround times of 2–3 h and 1.5 h, respect-
ively (see online supplementary table A1).18 All laborator-
ies participated in an external quality assurance
programme to evaluate their ability to detect, identify
and perform antibiotic sensitivity testing on staphylococci
from a variety of different specimens.19 MRSA isolates
were shipped to the central laboratory (University of
Antwerp, Belgium) for conﬁrmation of identiﬁcation.
Data collection
Research personnel from each hospital collected data
and implemented the interventions at their study site.
These personnel were from departments that supervise
infection control activities at the participating hospitals,
including infection control, infectious diseases and hos-
pital epidemiology departments. They were trained at
the study coordinating centre with regard to the study
protocol, the outcome deﬁnitions and the use of the
data collection tools prior to the start of the study to
ensure consistency of data collection across the hospitals.
Local microbiology laboratory data were reviewed to
Figure 1 Flow of study wards
through each phase of the study,
10 hospitals in nine countries
were enrolled and were allocated
to one of the three study arms
during the intervention phase.
The enhanced hand hygiene arm
used hand hygiene promotion;
the screening and decolonisation
arm used universal
meticillin-resistant
Staphylococcus aureus (MRSA)
screening coupled with contact
precautions and decolonisation
therapy with intranasal mupirocin
and chlorhexidine body washes
for identified MRSA carriers; the
combined arm used a
combination of hand hygiene
promotion and targeted MRSA
screening.
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Table 2 Summary of the timing and nature of infection control interventions for each study arm
Standard precautions HH promotion MRSA screening MRSA isolation MRSA decolonisation
Baseline phase: 6–7 months (1 March 2008 to 31 January 2009)*
Enhanced HH
arm
–† – – – –
Screening and
decolonisation
arm
– – – – –
Combined arm – – – – –
Intervention phase: 12 months (1 October 2008 to 31 January 2010)*
Enhanced HH
arm
Adherence to standard
precautions (eg, gloves and
other barriers as needed for
contact with mucous
membranes, wounds and body
fluids) during care of all patients
encouraged
HH promotion using the
WHO multi-modal HH
promotion method.15
Observation of 100
opportunities for HH per
ward per month
– – –
Screening and
decolonisation
arm
– – Universal screening of
patients admitted for
more than 24 h, on
admission then weekly
(see ‘MRSA screening
details’ in footnotes)
Patients MRSA colonised/infected
placed on contact precautions
(gown and gloves during contact).
Patients with MRSA placed in
single rooms or cohorted based
on local capacity. Pre-emptive
isolation of previously unknown
MRSA carriers pending screening
results not used
Patients MRSA colonised/
infected given twice-daily
intranasal mupirocin and
daily chlorhexidine body
washes (5 days)
Combined arm Adherence to standard
precautions (eg, gloves and
other barriers as needed for
contact with mucous
membranes, wounds and body
fluids) during care of all patients
encouraged
HH promotion using the
WHO multimodal HH
promotion method.15
Observation of 100
opportunities for HH per
ward per month
Targeted screening
based on risk factors
(see ‘MRSA screening
details’ in footnotes)
Patients MRSA colonised/infected
placed on contact precautions
(gown and gloves during contact).
Patients with MRSA placed in
single rooms or cohorted based
on local capacity. Pre-emptive
isolation of previously unknown
MRSA carriers pending screening
results not used
Patients MRSA colonised/
infected given topical
decolonisation therapy at
discretion of treating
clinicians
Washout phase: 6 months (1 October 2009 to 31 July 2010)*
Enhanced HH
arm
– – – – –
Screening and
decolonisation
arm
– – – – –
Continued
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obtain information regarding MRSA isolated from
screening and clinical cultures. Infections were moni-
tored by twice weekly ward visits to review medical
records and interview staff. Surgical site infection surveil-
lance occurred up to 30 days postprocedure (or
12 months after prosthetic device insertion).
HH adherence was monitored by the research person-
nel who had been trained and validated in the WHO
method of direct observation at the study coordinating
centre.15 A standardised observation form was used by all
centres. All hospitals collected data for 100 HH oppor-
tunities per ward during baseline and washout phases.20
HH observers were speciﬁcally instructed not to provide
feedback to healthcare workers concerning their HH
practices during these study phases and the observers
were independent of surgical ward staff, reducing the
likelihood of the Hawthorne effect, in which staff
improve their practices when they are aware that they are
being observed.21 During the intervention phase, there
was intensive monitoring of HH practices in wards using
the enhanced HH and combined strategies. In these
wards, 100 HH opportunities per ward per month were
observed as part of the intervention. Implementation of
contact precautions, decolonisation therapy and single
room isolation for MRSA carriers was randomly audited
each month. Signage of MRSA status and availability of
gowns, gloves and alcohol-based handrub for contact
with MRSA carriers was also audited.
Data regarding numbers of admissions, patient-days,
surgical procedures and level of stafﬁng were collected.
Owing to variation in the availability and quality of elec-
tronic medical record and pharmacy data between the
study sites, individual-level data (such as length of stay)
and antibiotic utilisation data for the surgical wards was
not collected as part of this study. Ward-level data were
submitted monthly to a central data management centre
through a password-protected secure online database
which included range, consistency and missing data
checks. Meetings, site visits and monthly teleconferences
were held to review data, ensure adherence to study pro-
tocols and address queries. Data were reviewed monthly
for completeness and 6 monthly for validity by telecon-
ferences with individual study sites. Institutional review
boards of all centres approved the study with a waiver of
individual informed consent.
Statistical analysis
The study was designed to detect a 30% difference in
nosocomial MRSA isolation rate assuming a baseline
rate of 1.0 clinical isolate per 100 susceptible patients
and an absolute difference of 10% between intervention
arms. Sample size calculations assumed a two-sided test,
a type I error rate of 0.05 and 80% power, taking the
wards as the unit of analysis. A minimum of 15 wards
were required per study arm.
Crude MRSA rates were calculated by study arm.
Adjusted incidence rate ratios (aIRR) were calculated
using multilevel Poisson segmented regression accounting
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for stepwise changes in MRSA level and changes in log-
linear trends associated with the interventions.22 This ana-
lysis allowed for two levels of random-effects: hospital-level
variation in intercepts and baseline trends and nested
ward-level variation in intercepts. It was adjusted for expos-
ure given by the monthly number of susceptible patients
or admissions per ward and allowed for extra-Poisson vari-
ation. Surgical subspecialty, baseline HH compliance, sea-
sonal effects (using calendar-month) and patient-to-nurse
ratios were adjusted for. Autocorrelation was accounted for
using a lagged dependent variable. A similar analysis was
performed for HH compliance, but used segmented
multilevel logistic regression, adjusting for ward-speciﬁc
baseline levels and trends, professional category, HH indi-
cation, patient-to-nurse ratios and monthly MRSA colonisa-
tion pressure (number of days patients known to be MRSA
colonised/infected were in the wards each month).
Planned subgroup analyses were performed by hospital
and for clean surgery wards (cardiothoracic, neuro, ortho-
paedic, plastic and vascular surgery) as studies have shown
that intranasal mupirocin, which is active against
Gram-positive organisms, may be more effective for surgi-
cal site infection prevention in clean compared with clean-
contaminated surgery (eg, general or gastrointestinal
surgery) where Gram-negative and anaerobic organisms
may play a larger role.23 As screening intensity varied in
the combined arm, a planned exploratory analysis of
MRSA outcome data was conducted to better quantify the
intervention effects. It accounted for stepwise changes and
log–linear trends in outcomes associated with the HH
intervention, as well as the monthly proportion of patients
screened and monthly cumulative screening rate on wards
to account for changes in trends of outcomes associated
with screening. Analyses were conducted with STATA
V.11.0 (STATACorp, USA).
RESULTS
During the study period, there were a total of 126 750
admissions and 99 638 surgical procedures on the study
wards. Baseline admission MRSA prevalence, without sys-
tematic screening of all admitted patients, was 0.8%
(269 of 33 608), ranging from 0.1% to 2.2% across surgi-
cal wards of each hospital. Baseline HH adherence
varied between hospitals (39.5% overall, 95% CI 38.1%
to 40.9%) as did use of targeted MRSA screening
(0–30.9% of admissions; table 1). Study characteristics
are shown in table 3 and online supplementary table A2.
Adherence to HH guidelines
In the enhanced HH and combined arms, HH compli-
ance improved in all centres with overall compliance
increasing from 49.3% (95% CI 47.2% to 51.4%) to 63.8%
(95% CI 63.2% to 64.4%) from baseline to intervention
phases (ﬁgure 2A). After multivariable analysis, starting
HH promotion was associated with a signiﬁcant immediate
increase in HH compliance (adjusted OR (aOR) 1.19,
95% CI 1.01 to 1.42; see online supplementary table A3).
However, this beneﬁt was not sustained after cessation of
the HH campaign with a signiﬁcant decreasing trend in
HH adherence of 9% per month (aOR for month postin-
tervention 0.91, 95% CI 0.85 to 0.97) during the washout
phase. In wards in the screening and decolonisation arm,
where no HH promotion occurred, compliance remained
low at 30.5% (95% CI 28.7% to 32.4%) at baseline and
23.9% (95% CI 22.0% to 25.9%) during the washout
phase.
Screening, contact precautions and decolonisation of
MRSA carriers
During the intervention phase, 9250 (75.3%) of 12 279
patients were screened on admission to wards in the
Table 3 Study characteristics by study period
Characteristic Baseline phase Intervention phase Washout phase
Duration (months) 6–7* 12 6
Total admissions (n) 33 608 63 810 29 332
Total patient-days (n) 264 035 496 975 249 119
Total surgical procedures (n) 27 768 49 747 22 123
Procedures in clean surgery wards (n)† 12 916 21 463 8787
Procedures in other types of surgery wards (n)† 14 852 28 284 13 336
Mean patient-to-nurse ratio (SD)‡ 6.55 (3.78) 6.67 (3.59) 6.87 (4.18)
Total number of patients MRSA positive on admission (%)§ 269 (0.8) 724 (1.1) 228 (0.8)
Number positive by clinical culture (%) 65 (0.2) 85 (0.1) 41 (0.1)
Number positive by screening swab (%) 204 (0.6) 639 (1.0) 187 (0.6)
*Baseline phase was 6 months in six hospitals and 7 months in four hospitals (two in the screening and decolonisation arm and one hospital
in each of the enhanced hand hygiene and combined arms).
†Clean surgery wards included cardiothoracic, neuro, orthopaedic, plastic and vascular surgery. Other types of surgery wards included
abdominal, general and urological surgery.
‡Calculated by dividing the mean patient load by mean number of nurses working on the ward at a given time (averaged over day, evening
and night shifts).
§By screening or clinical culture.
MRSA, meticillin-resistant Staphylococcus aureus.
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screening and decolonisation arm. Admission MRSA
prevalence was 2.1% (259 of 12 279), consisting of 27
patients (10.4%) with MRSA-positive clinical cultures and
232 patients (89.6%) identiﬁed by screening alone. PCR
screening was used in addition to chromogenic agar cul-
tures in 1047 (11.3%) of 9250 patients. Between baseline
and intervention phases in screening and decolonisation
wards, the proportion of audited MRSA carriers placed
on contact precautions increased (from 81.1% to 90.7%),
as did administration of decolonisation therapy (from
34.4% to 69.8%; ﬁgure 3). However, the proportion of
audited MRSA carriers in single rooms decreased (from
67.8% to 40.1%), possibly due to a shortage of rooms for
the higher number of identiﬁed MRSA carriers. Reasons
for non-adherence to decolonisation therapy included
discharge prior to an MRSA-positive result, discharge
prior to commencement of decolonisation therapy or the
patient declining the intervention.
Screening occurred to a lesser extent in the other study
arms (ﬁgure 2B). About 10% of admissions to wards in
the enhanced HH arm were screened throughout the
study. In wards in the combined arm, screening increased
from 9.2% to 22.3%, then 36.9% during baseline, inter-
vention and washout phases, respectively. In this arm,
adherence to contact precautions was high throughout
the study (93.0–99.6%), but only 32.9% of patients with
MRSA at baseline and 35.9% of patients during the inter-
vention phase received decolonisation therapy (ﬁgure 3).
Nosocomial MRSA isolation rate from clinical cultures
Crude MRSA isolation rates from clinical cultures
decreased in all study arms during the intervention
phase (enhanced HH arm: from 0.99 to 0.80; screening
and decolonisation arm: from 0.47 to 0.23; combined
arm: from 0.55 to 0.36; p=0.04; per 100 susceptible
patients; table 4). After adjusting for clustering and
potential confounders with multilevel segmented
Poisson regression (table 5 and online supplementary
table A4 for full model), the start of HH promotion in
the enhanced HH arm was associated with an immediate
Figure 2 Implementation of the
interventions, the top panel (A)
shows the monthly hand hygiene
(HH) compliance rates for
hospitals in the enhanced HH
and combined arms that used HH
promotion campaigns. The solid
dots represent the observed
compliance rates while the lines
represent the predicted
compliance rates based on the
regression model. The bottom
panel (B) shows the proportion of
patients screened on admission
to the study wards by study arm.
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Figure 3 Adherence to contact precautions, decolonisation and isolation measures for meticillin-resistant Staphylococcus
aureus (MRSA) carriers, this figure shows the distribution of monthly adherence to infection control measures for randomly
audited patients known to be colonised or infected with MRSA for each study arm. The top panel (A) shows adherence to
implementation of contact precautions, decolonisation therapy and isolation in single rooms. The middle panel (B) shows the
presence of signage of MRSA status on the patients’ room, bed or nursing chart. The bottom panel (C) shows the availability of
gowns, gloves and alcohol-based handrub in or at the entrance of the room. The horizontal line in each box represents the
median, the box represents the interquartile range and the vertical lines represent the minimum and maximum values.
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Table 4 Crude nosocomial MRSA incidence rates and incidence rate ratios by study arm for each study period*
Outcome Baseline phase Intervention phase Washout phase
Crude IRR (95% CI)
for intervention vs baseline
phases
Crude IRR (95% CI)
for washout vs intervention
phases
MRSA isolation rate from clinical cultures (number per 100 susceptible patients)
Enhanced hand hygiene 0.99 (181/183.47) 0.80 (279/349.50) 0.65 (106/163.83) 0.81 (0.67 to 0.98) 0.81 (0.65 to 1.01)
Screening and decolonisation 0.47 (31/66.61) 0.23 (28/122.56) 0.26 (17/66.04) 0.49 (0.29 to 0.82) 1.13 (0.62 to 2.06)
Combined 0.55 (47/85.35) 0.36 (60/165.23) 0.13 (8/63.04) 0.66 (0.45 to 0.97) 0.35 (0.17 to 0.73)
MRSA infection rate (number per 100 admissions)
Enhanced hand hygiene 0.58 (106/183.79) 0.50 (175/349.96) 0.45 (74/164.13) 0.87 (0.68 to 1.10) 0.90 (0.69 to 1.18)
Screening and decolonisation 0.24 (16/66.92) 0.19 (23/122.79) 0.17 (11/66.15) 0.78 (0.41 to 1.48) 0.89 (0.43 to 1.82)
Combined 0.29 (25/85.37) 0.19 (32/165.35) 0.13 (8/63.04) 0.66 (0.39 to 1.12) 0.66 (0.30 to 1.42)
MRSA surgical site infection rate (number per 100 surgical procedures)
Enhanced hand hygiene 0.60 (79/132.27) 0.49 (123/250.03) 0.42 (54/127.06) 0.82 (0.62 to 1.09) 0.86 (0.63 to 1.19)
Screening and decolonisation 0.26 (14/54.00) 0.15 (15/99.63) 0.16 (8/50.74) 0.58 (0.28 to 1.20) 1.05 (0.44 to 2.47)
Combined 0.20 (18/91.41) 0.14 (21/147.81) 0.07 (3/43.43) 0.72 (0.38 to 1.35) 0.49 (0.15 to 1.63)
MRSA bloodstream infection rate (number per 10 000 patient-days)
Enhanced hand hygiene 0.93 (14/15.0757) 0.56 (16/28.6667) 0.44 (6/13.5745) 0.60 (0.29 to 1.23) 0.79 (0.31 to 2.02)
Screening and decolonisation 0.17 (1/5.7754) 0.18 (2/11.2971) 0.17 (1/5.8473) 1.02 (0.09 to 11.28) 0.97 (0.09 to 10.65)
Combined 0.18 (1/5.5524) 0.00 (0/9.7337) 0.00 (0/5.4901) – –
*MRSA was defined as nosocomial if it was isolated from specimens collected more than 48 h after admission or within 30 days (or 12 months for infections of prosthetic devices) after discharge
from the surgical ward.
IRR, incidence rate ratio; MRSA, meticillin-resistant Staphylococcus aureus.
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Table 5 Multiple segmented multilevel Poisson regression models showing adjusted incidence rate ratios for changes in level and trend of nosocomial MRSA rates*
Variable
MRSA clinical isolates
(per 100 susceptible patients)
Total MRSA infections
(per 100 admissions)
MRSA surgical site infections
(per 100 procedures)
aIRR 95% CI p Value aIRR 95% CI p Value aIRR 95% CI p Value
Baseline phase
Trend 0.97 0.89 to 1.06 0.55 1.00 0.90 to 1.11 0.98 1.02 0.90 to 1.16 0.75
Intervention phase
Change in level
Enhanced hand hygiene 1.44 0.96 to 2.15 0.076 1.28 0.79 to 2.06 0.31 1.25 0.70 to 2.23 0.45
Screening and decolonisation 0.87 0.49 to 1.57 0.65 0.97 0.49 to 1.92 0.94 0.79 0.35 to 1.79 0.58
Combined 1.63 0.96 to 2.75 0.070 1.17 0.62 to 2.20 0.63 1.33 0.59 to 3.00 0.49
Change in trend
Enhanced hand hygiene 0.99 0.91 to 1.09 0.88 0.99 0.89 to 1.10 0.84 0.98 0.86 to 1.12 0.75
Screening and decolonisation 0.94 0.85 to 1.05 0.26 0.93 0.82 to 1.05 0.27 0.90 0.78 to 1.04 0.162
Combined 0.88 0.79 to 0.98 0.016 0.90 0.80 to 1.02 0.096 0.86 0.74 to 1.01 0.059
Washout phase
Change in level 1.90 0.91 to 3.95 0.087 1.52 0.66 to 3.51 0.32 1.90 0.69 to 5.27 0.21
Change in trend 1.02 0.91 to 1.15 0.74 1.00 0.88 to 1.15 0.95 0.95 0.80 to 1.12 0.53
*MRSA was defined as nosocomial if it was isolated from specimens collected more than 48 h after admission or within 30 days (or 12 months for infections of prosthetic devices) after discharge
from the surgical ward. The model used a lagged dependent variable to account for autocorrelation and adjusted for staffing (patient-to-nurse ratios), seasonal effects, type of surgical ward and
baseline hand hygiene compliance rates. The model also accounted for overdispersion. Random effects for intercepts at the hospital and ward levels and random baseline trends at the hospital
level were all significant and baseline trends were negatively correlated with intercepts (ie, hospitals with higher baseline MRSA rates tended to have larger decreases in baseline rates).
aIRR, adjusted incidence rate ratio; MRSA, meticillin-resistant Staphylococcus aureus.
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non-signiﬁcant increase in nosocomial MRSA isolation
rate (aIRR 1.44, 95% CI 0.96 to 2.15) with no change in
the trend in rates over time. In clean surgery wards, HH
promotion was associated with a non-signiﬁcant decreas-
ing monthly MRSA isolation rate (aIRR 0.89, 95% CI
0.78 to 1.01; table 6 and see online supplementary table
A5 for full model).
In the screening and decolonisation arm, there were
no signiﬁcant changes in MRSA isolation rates. However,
in clean surgery, this intervention was associated with a
reduction in MRSA clinical cultures of 15% per month
(aIRR 0.85, 95% CI 0.74 to 0.97).
In the combined arm (wards that used a combination
of HH promotion with targeted screening), there was a
signiﬁcant decreasing trend in MRSA isolation rate of
12% per month overall (aIRR 0.88, 95% CI 0.79 to 0.98)
and 18% per month in clean surgery (aIRR 0.82, 95%
CI 0.71 to 0.95). Observed and model-predicted MRSA
isolation rates from clinical cultures are illustrated in
ﬁgure 4A and online supplementary ﬁgure A1.
During the washout phase, MRSA clinical culture isola-
tion rates increased. A post hoc analysis of the washout
phase results by study arm showed that the increase in
MRSA rates was due to an abrupt increase in the level of
MRSA clinical cultures on cessation of the intervention
phase in all study arms, but particularly with the conclu-
sion of the intensive HH promotion campaign in the
combined arm (see online supplementary table A6).
Nosocomial MRSA infection rates
There were 470 nosocomial MRSA infections in total (335
(71.3%) surgical site, 41 (8.7%) bloodstream and 94
(20.0%) other infections). Crude infection rates decreased
over time in all study arms (table 4). After multivariable
analysis (table 5, ﬁgure 4B and online supplementary
table A4), enhanced HH promotion alone was not asso-
ciated with changes in MRSA infection rates. The screen-
ing/decolonisation and combined interventions resulted
in non-signiﬁcant decreasing trends in total MRSA infec-
tion (screening and decolonisation arm: aIRR 0.93, 95%
CI 0.82 to 1.05; combined arm: aIRR 0.90, 95% CI 0.80 to
1.02) and surgical site infection rates (table 5, ﬁgure 4C
and online supplementary table A4).
In clean surgery, the screening and decolonisation
strategy was associated with signiﬁcant reductions in
total MRSA infection rate of 17% per month (aIRR 0.83,
95% CI 0.69 to 0.99) and MRSA surgical site infection
rate of 19% per month (aIRR 0.81, 95% CI 0.66 to 1.00;
table 6 and online supplementary table A5).
Exploratory analysis to directly assess implemented
interventions
The exploratory analysis did not show any signiﬁcant
effects of HH promotion on nosocomial MRSA isolation
rates (see online supplementary table A7). The intensity
of admission screening was associated with a decreasing
trend in monthly MRSA isolation rate from clinical cul-
tures (aIRR 0.91/month with 100% compliance with
screening, 95% CI 0.85 to 0.98). A similar effect was
seen in the trend in MRSA infection rate (aIRR 0.92,
95% CI 0.85 to 0.99).
DISCUSSION
We found that implementation of individual interven-
tions in surgical wards, with either an enhanced HH pro-
motion strategy or universal MRSA screening with
contact precautions and decolonisation of MRSA car-
riers, was not effective in reducing MRSA rates. However,
using a combination of HH promotion and targeted
screening was associated with a reduction in MRSA isola-
tion rate from clinical cultures of 12% per month. When
the interventions were speciﬁcally evaluated in the sub-
group of clean surgery wards, the screening and decolon-
isation strategy was most effective. In these wards, this
intervention was associated with signiﬁcant reductions in
both MRSA clinical culture isolation rate of 15% per
month and MRSA infection rate of 17% per month.
This study is unique in that it directly compared strat-
egies individually and in combination using a large, pro-
spective, controlled design.10 In addition, we used a
planned exploratory analysis to separate out the individ-
ual effects of the HH and MRSA screening strategies.
Interventions were implemented and assessed under
operational conditions in 10 heterogeneous hospitals
across Europe and Israel with widely varying infection
control practices, stafﬁng, infrastructure and MRSA epi-
demiology, increasing the generalisability of our ﬁnd-
ings. This study has been reported using standard
reporting guidelines that are designed to maximise
transparency and scientiﬁc rigour of intervention studies
of healthcare associated infection.24
Our analysis, which adjusted for confounders, seasonal
effects and baseline MRSA trends, found no evidence
that enhanced HH promotion was effective. MRSA rates
are declining in many countries.25 Failing to account for
this would overestimate intervention effects. Overall base-
line HH compliance was 49% in study wards that used
the HH intervention. In settings where compliance is
already above about 50%, modelling studies suggest that
further increases in compliance will have rapidly dimin-
ishing returns for reducing MRSA transmission.26 In facil-
ities with lower HH compliance or higher MRSA rates,
this intervention may be more effective than we were able
to demonstrate. In addition, HH campaigns involve edu-
cation and behavioural change and are therefore unlikely
to have a short-term effect. Other studies have shown that
they may be beneﬁcial if activity is sustained over
years.27 28 Although we did not detect any intervention
effects of the HH promotion strategy, cessation of this
intervention was associated with an increase in MRSA
rates in our study, suggesting that discontinuing activities
to optimise HH practices may be detrimental.
Active MRSA surveillance identiﬁes the reservoir of
asymptomatic carriers, enabling early implementation
of contact precautions and decolonisation, which can
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Table 6 Multiple segmented multilevel Poisson regression models showing changes in nosocomial MRSA rates for the subgroup analysis of clean surgery only*
Variable
MRSA clinical isolates
(per 100 susceptible patients)
Total MRSA infections
(per 100 admissions)
MRSA surgical site infections
(per 100 procedures)
aIRR 95% CI p Value aIRR 95% CI p Value aIRR 95% CI p Value
Baseline phase
Trend 1.05 0.93 to 1.18 0.41 1.10 0.94 to 1.28 0.23 1.11 0.93 to 1.33 0.26
Intervention phase
Change in level
Enhanced hand hygiene 1.31 0.75 to 2.30 0.34 1.06 0.52 to 2.16 0.88 1.09 0.47 to 2.53 0.83
Screening and decolonisation 0.87 0.41 to 1.85 0.71 1.03 0.39 to 2.69 0.96 0.92 0.29 to 2.92 0.89
Combined 1.79 0.86 to 3.74 0.121 1.15 0.44 to 2.96 0.78 1.21 0.39 to 3.73 0.75
Change in trend
Enhanced hand hygiene 0.89 0.78 to 1.01 0.063 0.88 0.75 to 1.04 0.127 0.89 0.73 to 1.07 0.21
Screening and decolonisation 0.85 0.74 to 0.97 0.019 0.83 0.69 to 0.99 0.041 0.81 0.66 to 1.00 0.054
Combined 0.82 0.71 to 0.95 0.007 0.84 0.70 to 1.00 0.055 0.84 0.68 to 1.03 0.095
Washout phase
Change in level 3.01 1.05 to 8.63 0.041 2.21 0.61 to 8.04 0.23 2.59 0.59 to 11.46 0.21
Change in trend 0.96 0.81 to 1.15 0.67 0.91 0.73 to 1.12 0.37 0.86 0.67 to 1.09 0.21
aIRR, adjusted incidence rate ratio; MRSA, meticillin-resistant Staphylococcus aureus.
*MRSA was defined as nosocomial if it was isolated from specimens collected more than 48 h after admission or within 30 days (or 12 months for infections of prosthetic devices) after discharge
from the surgical ward. Clean surgery included cardiothoracic, neuro, orthopaedic, plastic and vascular surgery subspecialties. The model used a lagged dependent variable to account for
autocorrelation and adjusted for staffing (patient-to-nurse ratios), seasonal effects, type of surgical ward and baseline hand hygiene compliance rates. The model also accounted for
overdispersion. Random effects for intercepts at the hospital and ward levels and random baseline trends at the hospital level were all significant and baseline trends were negatively correlated
with intercepts (ie, hospitals with higher baseline MRSA rates tended to have larger decreases in baseline rates).
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reduce transmission.29 30 With universal screening, we
found that 90% of patients with MRSA would have
been missed using clinical cultures alone. However, our
results suggest that rather than universal screening of
all surgical patients admitted for more than 24 h,
selective screening in clean surgery wards or a combin-
ation of HH promotion and targeted screening of high-
risk patients may be more effective strategies. The rela-
tive burden of Gram-positive infections is greater in
clean compared to clean-contaminated surgery where
other pathogens, including bowel ﬂora, may be more
important.23 31 Thus, it is biologically plausible that
MRSA-speciﬁc interventions would potentially have a
greater impact in clean surgery. Indeed, intranasal
mupirocin has been shown to reduce surgical site infec-
tions in cardiothoracic and orthopaedic surgery, but is
less effective in general surgery.23 The commencement
of such decolonisation regimens prior to surgical pro-
cedures, which can be facilitated by rapid detection of
S aureus carriage with molecular tests, is likely a key
factor in the success of this approach.32 The use of
molecular tests in the latter part of the intervention
phase in our study could have signiﬁcantly contributed
to the reduction in MRSA rates seen over the period of
the intervention phase, particularly in clean surgery
wards.
Figure 4 Nosocomial meticillin-resistant Staphylococcus aureus (MRSA) rates by study arm, the top panel (A) shows the
nosocomial MRSA isolaton rates from clinical specimens. The middle panel (B) shows the nosocomial MRSA infection rates. The
bottom panel (C) shows the nosocomial MRSA surgical site infection rates. The solid dots represent the observed MRSA rates
while the lines represent the predicted MRSA rates based on the regression models.
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The exploratory analysis suggests that the screening
intensity, rather than HH promotion, explained the inter-
vention effects. It is curious, then, that universal screen-
ing did not perform better than HH promotion
combined with targeted screening. A signiﬁcant reduc-
tion in MRSA clinical cultures was seen with the com-
bined strategy despite the enrolment of only two
hospitals in this study arm. This suggests that the effect of
the combined intervention was robust. It is certainly bio-
logically plausible that using two interventions that aim to
control MRSA in different ways would be more effective
than use of single interventions. Although the universal
screening arm enrolled four hospitals, low baseline
MRSA rates in this arm and shortage of isolation rooms
for the larger number of identiﬁed MRSA carriers may
have reduced our ability to detect signiﬁcant effects. In
addition, targeted screening may have been more effect-
ive if it had identiﬁed ‘superspreaders’,33 facilitating
more efﬁcient use of resources including limited single
rooms. Modelling studies also demonstrate that targeted
screening has the advantage of increased cost-
effectiveness compared to universal screening for redu-
cing healthcare associated MRSA infections.34 35
This study adds to the conﬂicting literature regarding
active surveillance cultures. Our results apply to surgical
settings. The risk of MRSA infection in other wards, such
as intensive care units or general medical wards, would
differ due to variation in patient comorbidities and
exposure to invasive procedures or antibiotics. It is also
important to note that previous studies have used a
variety of interventions in combination with screening. In
some cases, the use of pre-emptive isolation in both study
arms36 or lack of decolonisation strategies,6 may have led
to effect sizes that studies had insufﬁcient power to
detect. Comparison of rapid screening to conventional
rather than no screening,36 differences in screening
methods,10 variation in MRSA strains37 or limitations in
study design and analyses10 11 are other potential expla-
nations for the conﬂicting results of screening studies.
There are some limitations to this study. Research per-
sonnel assessing HH, screening, decolonisation, contact
precautions and isolation practices were not blinded to
study assignment as they were responsible for implement-
ing the interventions. Decisions to take culture samples
were initiated by treating physicians, not research person-
nel and standardised deﬁnitions for infections were used,
reducing the likelihood of bias in the measurement of the
study outcomes by unblinded assessors. Although alloca-
tion of interventions was not randomised, we accounted
for differences in hospitals by adjusting for potential con-
founders and comparing outcomes between baseline and
intervention phases within the same study arm. We used
MRSA-positive clinical cultures as our primary outcome.
Although this measure does not distinguish between col-
onisation and infection, it can be a more sensitive marker
for changes in MRSA disease rates.38 We found the results
for MRSA clinical cultures similar to those for infections,
suggesting that this measure was clinically relevant. Patient
level data, such as age, comorbidities and length of stay
and antibiotic use were not measured for this study.
However, results were similar when each centre was
excluded in turn from the analysis (data not shown) so
changes in factors in individual centres are unlikely to
have had a major effect on study outcomes.
CONCLUSION
In surgical wards with relatively low MRSA prevalence, a
combination of enhanced standard infection control mea-
sures emphasising HH promotion and MRSA-speciﬁc (tar-
geted screening of high-risk patients) approaches was
required to reduce MRSA rates. Implementation of single
interventions was not effective, except in clean surgery
wards where MRSA screening coupled with contact pre-
cautions and decolonisation of identiﬁed MRSA carriers
was associated with signiﬁcant reductions in MRSA clinical
culture and infection rates. These ﬁndings are likely gener-
alisable to other settings with varying infection control
practices. In addition, the WHO multimodal HH promo-
tion strategy15 implemented in this study is already being
used in many parts of the world. Therefore our study,
which provides evidence that this intervention alone is
insufﬁcient to reduce MRSA rates, potentially has wide-
spread implications for best clinical practice recommenda-
tions and policy change. Further research regarding the
cost-effectiveness of these interventions will allow better
utilisation of limited healthcare resources.
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